Xeris Pharmaceuticals (NASDAQ:XERS) reported positive topline results from its Phase 2 study of XP-3924, a pramlintide-insulin co-formulation, in adults with Type 1 diabetes (T1D). The trial enrolled 18 adults with T1D...
Aptinyx (NASDAQ:APTX) completed enrollment for its Phase 2 study of NYX-783 for the treatment of post-traumatic stress disorder (PTSD). The 160 enrolled patients were randomized to receive either placebo, 10 mg of NYX...
InflaRx (NASDAQ:IFRX) reported encouraging topline results from the first 30 COVID-19 patients treated with IFX-1 in a Phase 2/3 trial. IFX-1 is a monoclonal anti-human complement factor C5a antibody designed to...
Kamada (NASDAQ, TASE:KMDA) completed manufacturing of the first batch of its plasma-derived immunoglobulin (IgG) product for the treatment of COVID-19 and the initial vials are available for compassionate use in Israel...
Exicure (NASDAQ:XCUR) dosed the first patient in the Phase 2 dose expansion portion of a clinical trial evaluating cavrotolimod for the treatment of Merkel cell carcinoma. The Phase 2 portion of the ongoing Phase 1b/2...
Titan Pharmaceuticals (NASDAQ:TTNP) launched a fully-virtual Probuphine implant Risk Evaluation and Mitigation Strategy (REMS) training and certification program for qualified health care providers (HCPs) who treat...
aTyr Pharma (NASDAQ:LIFE) dosed the first patient in a Phase 2 study evaluating ATYR1923, an immunomodulator, in COVID-19 patients with severe respiratory complications. The study will enroll 30 COVID-19-positive...
Soliton (NASDAQ:SOLY) presented new positive data from the company’s pivotal cellulite clinical trial at the American Academy of Dermatology 2020 virtual conference. The trial enrolled and treated 67 subjects at four...
X4 Pharmaceuticals (NASDAQ:XFOR) reported positive results from its ongoing Phase 2 trial of mavorixafor for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and...
The FDA granted Leap Therapeutics’ (NASDAQ:LPTX) DKN-01 orphan drug designation for the treatment of gastric and gastroesophageal junction cancer. DKN-01 is a humanized monoclonal antibody that targets the Dickkopf-1...
Aprea Therapeutics (NASDAQ:APRE) reported updated data from its Phase 1b/2 trial evaluating eprenetapopt, in combination with azacytidine, for the treatment of myelodysplastic syndromes (MDS) and acute myeloidleukemia...
Analysts for Raymond James and Cowen say two posters to be presented at the European Association of Urology (EAU) virtual conference in mid-July enhance the clinical utility of Profound Medical’s (NASDAQ:PROF;...
A Phase 2 trial supported by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) concluded that BiondVax Pharmaceuticals’ (NASDAQ:BVXV) M-001 universal influenza vaccine candidate achieved safety and...
Karyopharm Therapeutics (NASDAQ:KPTI) dosed the first patient in a Phase 1/2 clinical study evaluating oral selinexor in patients with newly diagnosed or recurrent glioblastoma (GBM). This global study is expected to...
Closely-held Soricimed Biopharma reported that the MD Anderson Cancer Center has resumed its investigator-initiated trial of Soricimed’s SOR-C13. MD Anderson completed the first cohort of the dose escalation phase of...
MacroGenics’ (NASDAQ:MGNX) margetuximab received FDA orphan drug designation for the treatment of gastric and gastroesophageal junction cancer. Margetuximab is currently being evaluated in a Phase 2/3 trial in...
Tenax Therapeutics (NASDAQ:TENX) reported positive results from a Phase 2 trial evaluating levosimendan for the treatment of patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH...
Idera Pharma (NASDAQ:IDRA) reported positive preliminary data from its Phase 2 trial of tilsotolimod, in combination with Opdivo and Yervoy, in immunotherapy-naive micro-satellite stable colorectal cancer (MSS-CRC)...
Menlo Therapeutics (NASDAQ:MNLO) reported positive results from its Phase 2 trial evaluating FCD105 or the treatment of moderate-to-severe acne vulgaris. The study enrolled 447 patients who received either FCD105, a 3%...
PharmAust (ASX:PAA) posted positive preliminary results in experiments aimed at inhibiting the virus that causes COVID-19. PharmAust, which traditionally is focused on repurposing existing drugs for cancer therapy, is...
Ocugen (NASDAQ:OCGN) is discontinuing the Phase 3 trial of OCU300 for ocular graft vs. host disease (oGVHD) based on results of a pre-planned interim sample size analysis conducted by an independent data monitoring...
Menlo Therapeutics’ (NASDAQ:MNLO) ZILXI received FDA approval for the treatment of inflammatory lesions of rosacea in adults. The company noted that ZILXI, a minocycline topical foam, is the first minocycline product of...